After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Zymeworks BC Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Zymeworks BC Inc is $666.62M. A total of 0.65 million shares were traded on the day, compared to an average of 552.93K shares.
In the most recent transaction, Galbraith Kenneth sold 5,706 shares of ZYME for 11.22 per share on Jan 08 ’24. After the transaction, the Chair & CEO now owns 23,762 company shares. In a previous transaction on Jan 08 ’24, Moore Paul Andrew sold 2,339 shares at 11.22 per share. ZYME shares that Chief Scientific Officer owns now total 7,367.
Among the insiders who sold shares, Astle Christopher disposed of 1,431 shares on Jan 08 ’24 at a per-share price of $11.22. This resulted in the SVP & Chief Financial Officer holding 6,503 shares of ZYME after the transaction. In another insider transaction, Galbraith Kenneth sold 18,198 shares at $10.65 per share on Jan 05 ’24. Company shares held by the Chair & CEO now total 29,468.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ZYME has a high of $13.14 and a low of $6.01.
As of this writing, ZYME has an earnings estimate of -$0.29 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.13 per share and a lower estimate of -$0.42. The company reported an EPS of -$0.41 in the last quarter, which was 12.80% higher than expectations of -$0.47.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ZYME’s latest balance sheet shows that the firm has $252.61M in Cash & Short Term Investments as of fiscal 2021. There were $32.33M in debt and $71.85M in liabilities at the time. Its Book Value Per Share was $6.57, while its Total Shareholder’s Equity was $249.09M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Buy with a score of 4.33.
